Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same author

L-DOPA influences transferrin-dependent iron release at the blood-brain barrier.

Fluids and barriers of the CNS·2026
Same author

The role of iron in driving sex-biased differences in cancer.

Cancer metastasis reviews·2026
Same author

Reimagining the contribution of iron in Parkinson's disease.

Neurobiology of disease·2026
Same author

Systemic iron availability differentially shapes tumor and brain iron handling in a sex-dependent manner in glioblastoma.

PloS one·2026
Same author

Tumor-associated macrophages promote ferroptosis resistance in glioblastoma by stimulating iron-loaded extracellular vesicle release.

Journal of neuro-oncology·2026
Same journal

Age-related differences in motor learning, sensorimotor neurochemistry, and cortical reactivity co-occur but are dissociated.

Neurobiology of aging·2026
Same journal

How cognition and hearing-related measures covary with hippocampal subfield features from structural MRI in younger and older adults.

Neurobiology of aging·2026
Same journal

Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals.

Neurobiology of aging·2026
Same journal

Review of current research practices in social and structural determinants of health data collection in Canadian longitudinal cohorts of aging and dementia.

Neurobiology of aging·2026
Same journal

Global brain maintenance predicts well-preserved cognitive function: A pooled analysis of three longitudinal population-based Swedish cohorts.

Neurobiology of aging·2026
Same journal

Midlife insulin resistance and brain beta-amyloid accumulation as predictors of change in late-life cognitive function - A 20-year follow-up study.

Neurobiology of aging·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

HFE polymorphisms affect cellular glutamate regulation.

Ryan M Mitchell1, Sang Y Lee, Zachary Simmons

  • 1George M. Leader Family Laboratory, Department of Neurosurgery, Pennsylvania State University College of Medicine/Milton S. Hershey Medical Center, 500 University Drive (H110), Hershey, PA 17033, USA.

Neurobiology of Aging
|June 30, 2009
PubMed
Summary
This summary is machine-generated.

The HFE H63D gene variant increases glutamate toxicity by altering calcium levels and glutamate transport. This finding links common HFE variants to neurodegenerative disease mechanisms.

More Related Videos

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

Related Experiment Videos

Last Updated: Jun 22, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
10:46

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

Area of Science:

  • Neurogenetics
  • Cellular Biology
  • Neurodegenerative Diseases

Background:

  • HFE gene variants are common in Caucasians.
  • The H63D HFE variant is linked to neurodegenerative diseases.
  • Mechanisms underlying this association require elucidation.

Purpose of the Study:

  • To investigate if HFE H63D variant cells exhibit a phenotype promoting glutamate toxicity.
  • To explore the cellular mechanisms, including calcium and iron regulation, involved.

Main Methods:

  • Developed neuroblastoma cell lines with different HFE polymorphisms.
  • Assessed calcium-induced glutamate secretion and cellular glutamate uptake.
  • Utilized astrocytoma cell lines for endogenous HFE expression confirmation.

Main Results:

  • H63D HFE expression increased calcium-induced glutamate secretion.
  • Cellular glutamate uptake was decreased in H63D variant cells.
  • Altering cellular iron mimicked polymorphism-associated glutamate secretion changes.
  • Intracellular calcium levels were altered in a genotype-specific manner.
  • Minocycline and Trolox effects on glutamate uptake varied by HFE genotype, implicating oxidative stress.

Conclusions:

  • HFE H63D variant cells promote glutamate toxicity through altered calcium homeostasis and glutamate transport.
  • HFE-dependent cellular effects extend beyond iron regulation.
  • The H63D HFE variant may contribute to neurodegeneration via excitotoxicity.